Given the emerging evidence suggesting crucial roles of VEGF-C/VEGFR3 axis in cancer progression, multiple therapeutic strategies for VEGF-C/VEGFR3-targeted therapies, including small molecule VEGFR3 inhibitors, monoclonal antibodies targeting VEGF-C, and neutralizing antibodies or peptides that block VEGFR3 signaling, have been developed [33]. Here, FLT4 is linked to cancer.